99 related articles for article (PubMed ID: 15010054)
1. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities.
Huber B; Bömmel W; Hauser I; Horstmann V; Liem S; May T; Meinert T; Robertson E; Schulz L; Seidel M; Tomka-Hoffmeister M; Wagner W
Seizure; 2004 Apr; 13(3):168-75. PubMed ID: 15010054
[TBL] [Abstract][Full Text] [Related]
2. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
4. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy.
Lee GH; Kim BM; Kang JK; Lee SA
Seizure; 2013 Apr; 22(3):185-8. PubMed ID: 23280273
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
Perry MS; Benatar M
Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
von Stuelpnagel C; Holthausen H; Kluger G
Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
[TBL] [Abstract][Full Text] [Related]
8. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Kinirons P; McCarthy M; Doherty CP; Delanty N
Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam in refractory epilepsy: a prospective observational study.
Mohanraj R; Parker PG; Stephen LJ; Brodie MJ
Seizure; 2005 Jan; 14(1):23-7. PubMed ID: 15642496
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy.
Giroux PC; Salas-Prato M; Théorêt Y; Carmant L
Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014
[TBL] [Abstract][Full Text] [Related]
12. Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S
Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474
[TBL] [Abstract][Full Text] [Related]
13. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
Atkins M; Nikanorova M
Seizure; 2011 Oct; 20(8):635-9. PubMed ID: 21752673
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam for people with mental retardation and refractory epilepsy.
Kelly K; Stephen LJ; Brodie MJ
Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy.
Grosso S; Cordelli DM; Franzoni E; Coppola G; Capovilla G; Zamponi N; Verrotti A; Morgese G; Balestri P
Seizure; 2007 Jun; 16(4):345-50. PubMed ID: 17368928
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.
Coppola G; Mangano S; Tortorella G; Pelliccia A; Fels A; Romano A; Nardello R; Habetswallner F; Licciardi F; Operto FF; Pascotto A
Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
[TBL] [Abstract][Full Text] [Related]
20. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]